Form 144 FRACTYL HEALTH, INC. Filed by: Caplan Jay David
Fractyl Health, Inc. (GUTS)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
GUTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GUTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GUTS alerts
High impacting Fractyl Health, Inc. news events
Weekly update
A roundup of the hottest topics
GUTS
News
- Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024GlobeNewswire
- Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024GlobeNewswire
GUTS
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- GUTS's page on the SEC website